-
EP3052485
Procédure d'examen
Extrait du Registre européen des brevets
EP Présentation générale: EP3052485
| EP3052485 - COMPOSÉS HÉTÉROCYCLIQUES ET LEURS UTILISATIONS [Cliquez sur ce lien avec le bouton droit de la souris pour le conserver dans vos signets] | Statut | Aucune opposition formée dans le délai Statut actualisé le 03.06.2022 Base de données mise à jour au 14.11.2024 | |
| Précédent | Le brevet a été délivré Statut actualisé le 25.06.2021 | ||
| Précédent | La délivrance du brevet est envisagée Statut actualisé le 07.02.2021 | ||
| Précédent | L'examen est en cours Statut actualisé le 11.11.2020 | ||
| Précédent | La délivrance du brevet est envisagée Statut actualisé le 29.06.2020 | ||
| Précédent | L'examen est en cours Statut actualisé le 09.06.2017 | Dernier événement Tooltip | 06.09.2024 | Extinction du brevet dans un Etat contractant Nouvel/nouveaux État(s): MT | publié le 09.10.2024 [2024/41] | Demandeur(s) | Pour tous les Etats désignés Infinity Pharmaceuticals, Inc. 1100 Massachusetts Avenue, 4th Floor Cambridge, MA 02138 / US | [2021/30] |
| Précédent [2016/32] | Pour tous les Etats désignés Infinity Pharmaceuticals, Inc. 780 Memorial Drive Cambridge, MA 02139 / US | Inventeur(s) | 01 /
CASTRO, Alfredo, C. 14 Kelly Drive Woburn, MA 01801 / US | 02 /
EVANS, Catherine, A. 83 Jaques Street Somerville, MA 02145 / US | 03 /
JANARDANANNAIR, Somarajannair 10 Totman Drive, Apt. 7 Woburn, WA 01801 / US | 04 /
LESCARBEAU, Andre 99 Porter Street 1 Somerville, MA 02143 / US | 05 /
LIU, Tao 11 Frost Circle Wellesley, MA 02482 / US | 06 /
TREMBLAY, Martin, R. 47 Heywood Avenue Melrose, MA 02176 / US | [2021/30] |
| Précédent [2016/32] | 01 /
CASTRO, Alfredo, C. 14 Kelly Drive Woburn, MA 01801 / US | ||
| 02 /
EVANS, Catherine, A. 83 Jaques Street Somerville, MA 02145 / US | |||
| 03 /
JANARDANANNAIR, Somarajannair 111 Locust Street Apt. Th-78 Woburn, WA 01801 / US | |||
| 04 /
LESCARBEAU, Andre 99 Porter Street 1 Somerville, MA 02143 / US | |||
| 05 /
LIU, Tao 15 Sherborne Circle Ashland, MA 01721 / US | |||
| 06 /
TREMBLAY, Martin, R. 47 Heywood Avenue Melrose, MA 02176 / US | Mandataire(s) | Abel & Imray LLP Westpoint Building James Street West Bath BA1 2DA / GB | [N/P] |
| Précédent [2021/30] | Abel & Imray Westpoint Building James Street West Bath BA1 2DA / GB | ||
| Précédent [2016/32] | Beresford Crump LLP 16 High Holborn London WC1V 6BX / GB | Numéro de la demande, date de dépôt | 14786409.4 | 03.10.2014 | [2016/32] | WO2014US59026 | Numéro de priorité, date | US201361887259P | 04.10.2013 Format original publié: US 201361887259 P | US201361888958P | 09.10.2013 Format original publié: US 201361888958 P | US201461938026P | 10.02.2014 Format original publié: US 201461938026 P | [2016/32] | Langue de dépôt | EN | Langue de la procédure | EN | Publication | Type: | A1 Demande avec rapport de recherche | N°: | WO2015051244 | Date: | 09.04.2015 | Langue: | EN | [2015/14] | Type: | A1 Demande avec rapport de recherche | N°: | EP3052485 | Date: | 10.08.2016 | Langue: | EN | La demande publiée par l'OMPI le 09.04.2015, dans une des langues officielles de l'OEB, remplace la publication de la demande de brevet européen. | [2016/32] | Type: | B1 Fascicule de brevet | N°: | EP3052485 | Date: | 28.07.2021 | Langue: | EN | [2021/30] | Rapport(s) de recherche | Rapport de recherche internationale - publié le: | EP | 09.04.2015 | Classification | IPC: | C07D403/12, C07D401/14, C07D401/12, C07D403/14, C07D417/14, C07D471/04, C07D487/04, A61K31/4725, A61K31/517, A61P35/00 | [2016/32] | CPC: |
C07D487/04 (EP,IL,KR,US);
C07D403/12 (EP,IL,KR,US);
A61K31/4725 (IL,KR);
A61K31/517 (IL,KR);
A61K31/519 (IL,KR);
A61P29/00 (EP);
A61P35/00 (EP);
A61P35/02 (EP);
A61P37/00 (EP);
A61P37/06 (EP);
A61P43/00 (EP);
C07D401/12 (EP,IL,KR,US);
C07D401/14 (EP,IL,KR,US);
C07D403/14 (EP,IL,KR,US);
C07D417/14 (EP,IL,US);
| Etats contractants désignés | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2016/32] | Etats autorisant lextension | BA | 06.04.2016 | ME | 06.04.2016 | Titre | Allemand: | HETEROCYCLISCHE VERBINDUNGEN UND VERWENDUNGEN DAVON | [2016/32] | Anglais: | HETEROCYCLIC COMPOUNDS AND USES THEREOF | [2016/32] | Français: | COMPOSÉS HÉTÉROCYCLIQUES ET LEURS UTILISATIONS | [2016/32] | Entrée dans la phase régionale | 06.04.2016 | Taxe nationale de base payée | 06.04.2016 | Taxe(s) de désignation payée(s) | 06.04.2016 | Taxe d'examen payée | Procédure d'examen | 06.04.2016 | Requête en examen déposée [2016/32] | 19.12.2016 | Modification par le demandeur (revendications et/ou déscription) | 13.06.2017 | Envoi d'une notification de la division d'examen (délai : M06) | 21.12.2017 | Réponse à une notification de la division dexamen | 20.08.2018 | Envoi d'une notification de la division d'examen (délai : M06) | 20.02.2019 | Réponse à une notification de la division dexamen | 08.07.2019 | Envoi d'une notification de la division d'examen (délai : M06) | 20.01.2020 | Réponse à une notification de la division dexamen | 30.06.2020 | Notification relative à l'intention de délivrer le brevet | 10.11.2020 | Désaccord du demandeur concernant la notification relative à l'intention de délivrer un brevet ou reprise de la procédure d'examen par l'OEB | 08.02.2021 | Notification relative à l'intention de délivrer le brevet | 16.06.2021 | Taxe de délivrance payée | 16.06.2021 | Taxe publication/d‘impression payée | 16.06.2021 | Réception des traductions de la/des revendication(s) | Demande(s) divisionnaire(s) | EP21188077.8 / EP3964507 | Opposition(s) | 29.04.2022 | Aucune opposition formée dans le délai imparti [2022/27] | Taxes payées | Taxe annuelle | 27.10.2016 | Taxe annuelle Année du brevet 03 | 27.10.2017 | Taxe annuelle Année du brevet 04 | 29.10.2018 | Taxe annuelle Année du brevet 05 | 28.10.2019 | Taxe annuelle Année du brevet 06 | 27.10.2020 | Taxe annuelle Année du brevet 07 |
| Dérogation à la compétence Tooltip exclusive de la juridiction unifiée du brevet | Voir le Registre de la juridiction unifiée du brevet pour les données relatives à la dérogation | ||
| La juridiction unifiée du brevet assume l'entière responsabilité de l'exactitude, de l'exhaustivité et de la qualité des données présentées sous le lien fourni. | Extinctions durant la phase d’opposition Tooltip | AL | 28.07.2021 | EE | 28.07.2021 | HR | 28.07.2021 | LT | 28.07.2021 | LV | 28.07.2021 | MC | 28.07.2021 | MK | 28.07.2021 | MT | 28.07.2021 | RS | 28.07.2021 | SI | 28.07.2021 | SK | 28.07.2021 | SM | 28.07.2021 | IS | 28.11.2021 | [2024/41] |
| Précédent [2024/22] | AL | 28.07.2021 | |
| EE | 28.07.2021 | ||
| HR | 28.07.2021 | ||
| LT | 28.07.2021 | ||
| LV | 28.07.2021 | ||
| MC | 28.07.2021 | ||
| MK | 28.07.2021 | ||
| RS | 28.07.2021 | ||
| SI | 28.07.2021 | ||
| SK | 28.07.2021 | ||
| SM | 28.07.2021 | ||
| IS | 28.11.2021 | ||
| Précédent [2022/33] | AL | 28.07.2021 | |
| EE | 28.07.2021 | ||
| HR | 28.07.2021 | ||
| LT | 28.07.2021 | ||
| LV | 28.07.2021 | ||
| MC | 28.07.2021 | ||
| RS | 28.07.2021 | ||
| SI | 28.07.2021 | ||
| SK | 28.07.2021 | ||
| SM | 28.07.2021 | ||
| IS | 28.11.2021 | ||
| Précédent [2022/29] | AL | 28.07.2021 | |
| EE | 28.07.2021 | ||
| HR | 28.07.2021 | ||
| LT | 28.07.2021 | ||
| LV | 28.07.2021 | ||
| RS | 28.07.2021 | ||
| SI | 28.07.2021 | ||
| SK | 28.07.2021 | ||
| SM | 28.07.2021 | ||
| IS | 28.11.2021 | ||
| Précédent [2022/26] | EE | 28.07.2021 | |
| HR | 28.07.2021 | ||
| LT | 28.07.2021 | ||
| LV | 28.07.2021 | ||
| RS | 28.07.2021 | ||
| SK | 28.07.2021 | ||
| SM | 28.07.2021 | ||
| IS | 28.11.2021 | ||
| Précédent [2022/24] | EE | 28.07.2021 | |
| HR | 28.07.2021 | ||
| LT | 28.07.2021 | ||
| LV | 28.07.2021 | ||
| RS | 28.07.2021 | ||
| SK | 28.07.2021 | ||
| IS | 28.11.2021 | ||
| Précédent [2022/10] | HR | 28.07.2021 | |
| LT | 28.07.2021 | ||
| LV | 28.07.2021 | ||
| RS | 28.07.2021 | ||
| IS | 28.11.2021 | ||
| Précédent [2022/08] | LT | 28.07.2021 | Cité dans | Recherche internationale | [A]WO2012037204 (EXELIXIS INC [US], et al) [A] 1-46 * claims 1, 21 *; | [I]WO2013012918 (INFINITY PHARMACEUTICALS INC [US], et al) [I] 1-18,23,24,26-32,34,35,37-46 * claims 1, 9, 53 *; | [I]US2013029982 (CASTRO ALFREDO C [US], et al) [I] 1-18,23,24,26-32,34,35,37-46 * claims 1, 4, 41 *; | [I]US2013053362 (CASTRO ALFREDO C [US], et al) [I] 1-18,23,24,26-32,34,35,37-46 * claims 1, 12, 37 *; | [IP]WO2013154878 (INFINITY PHARMACEUTICALS INC [US], et al) [IP] 1* claims 1, 2, 95 * | Examen | EP3119397 | par le demandeur | US3536809 | US3598123 | US3845770 | US3916899 | US4008719 | US4270537 | US4596556 | US4790824 | US4886499 | WO9005719 | US4940460 | US4941880 | US4992445 | US5001139 | US5015235 | US5023252 | US5059595 | US5064413 | US5073543 | US5120548 | US5141496 | US5190521 | US5312335 | US5328483 | EP0606046 | US5334144 | US5339163 | US5354556 | US5383851 | US5417662 | US5466220 | US5480381 | US5503627 | US5520639 | US5527288 | WO9627583 | WO9633172 | US5569189 | US5591767 | US5599302 | WO9713537 | US5639476 | US5639480 | EP0780386 | US5649912 | US5674533 | WO9737705 | US5704911 | WO9803516 | WO9807697 | US5733566 | US5739108 | WO9830566 | WO9833768 | WO9834918 | WO9834915 | US5861510 | US5863949 | US5891474 | US5893397 | WO9929667 | US5922356 | WO9934850 | EP0931788 | WO9952910 | WO9952889 | US5972891 | US5980945 | US5993412 | US5993855 | US6045830 | US6087324 | US6113943 | US6197350 | WO0119800 | WO0126644 | WO0127135 | US6248363 | WO0149279 | US6264970 | US6267981 | WO0174344 | WO0181346 | US2002006931 | US6376461 | US6419961 | WO03011219 | US2003113828 | US6589548 | US2003158195 | US6613358 | WO03088970 | US2003229090 | US6699500 | WO2004020599 | US6800620 | WO2005013800 | US2005075306 | WO2005033288 | WO2005032343 | WO2005042700 | US2005232969 | US2005267059 | WO2005113556 | WO2006028958 | WO2006050351 | WO2006078283 | US2006205731 | US2006247262 | US2007021493 | US2007060546 | WO2007054623 | WO2007059157 | US7230004 | US2007219152 | US2007219195 | WO2007120827 | WO2007131201 | US2008114024 | WO2008070357 | WO2008110611 | WO2008112913 | WO2008118468 | WO2008131354 | US2008287420 | US2008293754 | US2008293755 | US2009012031 | US2009171089 | WO2009088986 | WO2009088880 | WO2009088990 | WO2009088086 | US2009203010 | WO2009114870 | US2009306214 | US2009312310 | WO2010006086 | US2010029693 | US2010048567 | WO2010036380 | US2010093625 | US2010152159 | US2010152182 | US2010222420 | US7812164 | US2010286114 | US2010305096 | US2010305084 | US2010316649 | WO2011008302 | US2011046165 | US2011053897 | WO2011041399 | US2011112098 | US2011245205 | US2011251216 | US2011275655 | US2011286990 | US2012014962 | US2012027834 | US2012071418 | US2012093913 | US2012101275 | US2012130073 | US2012142671 | US2012184526 | US2012220582 | US2012277192 | US2012309735 | US2013040906 | US2013040984 | US2013090309 | US2013116260 | WO2013082540 | US2013165431 | US2013195843 | - GAESTEL ET AL., CURRENT MEDICINAL CHEMISTRY, (2007), vol. 14, pages 2214 - 2234 | - EDGAR ET AL., CANCER RESEARCH, (2010), vol. 70, no. 3, pages 1164 - 1172 | - J. PHARMACEUTICAL SCIENCES, (1977), vol. 66, pages 1 - 19 | - BUNDGARD, H., Design ofProdrugs, ELSEVIER, (1985), pages 7 - 9,21-24 | - HIGUCHI, T. ET AL., "Pro-drugs as Novel Delivery Systems", A. C.S. SYMPOSIUM SERIES, vol. 14 | - Burger's Medicinal Chemistry and Drug Discovery, (1995), pages 172 - 178,949- | - WILEN ET AL., TETRAHEDRON, (1977), vol. 33, page 2725 | - Tables of Resolving Agents and Optical Resolutions, UNIV. OF NOTRE DAME PRESS, (1972), page 268 | - Handbook of Chemistry and Physics | - SEFTON, CRC CRIT. REF. BIOMED. ENG., (1987), vol. 14, page 201 | - BUCHWALD ET AL., SURGERY, (1980), vol. 88, page 507 | - SAUDEK ET AL., N. ENGL. J MED., (1989), vol. 321, page 574 | - GOODSON, MEDICAL APPLICATIONS OF CONTROLLED RELEASE, (1984), vol. 2, pages 115 - 138 | - LANGER, SCIENCE, (1990), vol. 249, pages 1527 - 1533 | - VANHAESEBROECK, B. ET AL., ANNU REV BIOCHEM., (2001), vol. 70, pages 535 - 602 | - FUNG-LEUNG WP, CELL SIGNAL., (2011), vol. 23, no. 4, pages 603 - 8 | - HARRIS, SJ ET AL., CURR OPIN INVESTIG DRUGS, (2009), vol. 10, no. 11, pages 1151 - 62 | - ROMMEL C. ET AL., NAT REV IMMUNOL, (2007), vol. 7, no. 3, pages 191 - 201 | - DURAND CA ET AL., J IMMUNOL., (2009), vol. 183, no. 9, pages 5673 - 84 | - DIL N; MARSHALL AJ, MOL IMMUNOL., (2009), vol. 46, no. 10, pages 1970 - 8 | - AL-ALWAN MM ET AL., J IMMUNOL., (2007), vol. 178, no. 4, pages 2328 - 35 | - ZHANG TT ET AL., J LLERGY CLIN IMMUNOL., (2008), vol. 122, no. 4, pages 811 - 819.E2 | - SRINIVASAN L ET AL., CELL, (2009), vol. 139, no. 3, pages 573 - 86 | - HIRSCH ET AL., "Central Role for G Protein-Coupled Phosphoinositide 3-Kinase y in Inflammation", SCIENCE, (2000), vol. 287, pages 1049 - 1053 | - SASAKI ET AL., "Function of PI3Ky in Thymocyte Development, T Cell Activation, and Neutrophil Migration", SCIENCE, (2000), vol. 287, doi:doi:10.1126/science.287.5455.1040, pages 1040 - 1046, XP002214938 DOI: http://dx.doi.org/10.1126/science.287.5455.1040 | - LI ET AL., "Roles of PLC-?2 and -?3 and PI3Ky in Chemoattractant-Mediated Signal Transduction", SCIENCE, (2000), vol. 287, pages 1046 - 1049 | - RANDIS ET AL., EUR. J IMMUNOL., (2008), vol. 38, no. 5, pages 1215 - 24 | - TAKEDA ET AL., J ALLERGY CLIN. IMMUNOL., (2009), vol. 123, pages 805 - 12 | - SASAKI ET AL., SCIENCE, (2000), vol. 287, pages 1040 - 46 | - COMERFOLD, PLOS ONE, (2012), vol. 7, page E45095 | - ROLLER ET AL., "Blockade of Phosphatidylinositol 3-Kinase (PI3K)? or PI3Ky Reduces IL-17 and Ameliorates Imiquimod-Induced Psoriasis-like Dermatitis", J IMMUNOL., (2012), vol. 189, doi:doi:10.4049/jimmunol.1103173, pages 4612 - 4620, XP055065662 DOI: http://dx.doi.org/10.4049/jimmunol.1103173 | - SCHMID ET AL., CANCER CELL, (2011), vol. 19, pages 715 - 27 | - SUBRAMANIAM ET AL., CANCER CELL, (2012), vol. 21, pages 459 - 472 | - BURGER, "Inhibiting B-Cell Receptor Signaling Pathways in Chronic Lymphocytic Leukemia", CURR. MEMATOL MALIG. REP., (2012), vol. 7, doi:doi:10.1007/s11899-011-0104-z, pages 26 - 33, XP035015776 DOI: http://dx.doi.org/10.1007/s11899-011-0104-z | - RUCKLE ET AL., NATURE REV., DRUG DISCOVERY, (2006), vol. 5, pages 903 - 18 | - COMERFORD ET AL., PLOS ONE, (2012), vol. 7, page E45095 | - LI ET AL., SCIENCE, (2000), vol. 287, page 1046,49 | - HIRSCH ET AL., SCIENCE, (2000), vol. 287, pages 1049 - 53 | - EDLING ET AL., HUMAN CANCERBIOLOGY, (2010), vol. 16, no. 2, pages 4928 - 37 | - KYBURZ ET AL., SPRINGER SEMIN. IMMUNOPATHOLOGY, (2003), vol. 25, pages 79 - 90 | - LEE ET AL., FASEB J., (2006), vol. 20, pages 455 - 65 | - HAYLOCK-JACOB ET AL., J. AUTOIMMUNITY, (2011), vol. 36, pages 278 - 87 | - SCHMID ET AL., CANCER CELL, (2011), vol. 19, no. 6, pages 715 - 27 | - SUBRAMANIAM ET AL., CANCER CELL, (2012), vol. 21, pages 459 - 72 | - CLAYTON E ET AL., J EXP MED., (2002), vol. 196, no. 6, pages 753 - 63 | - BILANCIO A ET AL., BLOOD, (2006), vol. 107, no. 2, pages 642 - 50 | - OKKENHAUG K. ET AL., SCIENCE, (2002), vol. 297, no. 5583, pages 1031 - 4 | - ALWAN MM ET AL., J IMMUNOL., (2007), vol. 178, no. 4, pages 2328 - 35 | - ZHANG TT ET AL., J ALLERGY CLIN IMMUNOL., (2008), vol. 122, no. 4, pages 811 - 819.E2 | - GARÇON F. ET AL., BLOOD, (2008), vol. 111, no. 3, pages 1464 - 71 | - OKKENHAUG K ET AL., J IMMUNOL., (2006), vol. 177, no. 8, pages 5122 - 8 | - SOOND DR ET AL., BLOOD, (2010), vol. 115, no. 11, pages 2203 - 13 | - REIF K, J IMMUNOL., (2004), vol. 173, no. 4, pages 2236 - 40 | - JI H. ET AL., BLOOD, (2007), vol. 110, no. 8, pages 2940 - 7 | - WEBB LM ET AL., J IMMUNOL., (2005), vol. 175, no. 5, pages 2783 - 7 | - LIU D ET AL., JLMMUNOL., (2010), vol. 184, no. 6, pages 3098 - 105 | - HAYLOCK-JACOBS S ET AL., JAUTOIMMUN., (2011), vol. 36, no. 3-4, pages 278 - 87 | - JARMIN SJ ET AL., JCLIN INVEST., (2008), vol. 118, no. 3, pages 1154 - 64 | - PURI; GOLD, "Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory disease and B-cell malignancies", FRONT. IMMUNOL., (2012), vol. 3, page 256 | - BUITENHUIS ET AL., "The role of the PI3k-PKB signaling module in regulation of hematopoiesis", CELL CYCLE, (2009), vol. 8, no. 4, pages 560 - 566 | - HOELLENRIEGEL; BURGER, "Phosphoinositide 3'-kinase delta: turning off BCR signaling in Chronic Lymphocytic Leukemia", ONCOTARGET, (2011), vol. 2, no. 10, pages 737 - 738 | - CUSHING ET AL., "PI3K? and PI3Ky as Targets for Autoimmune and Inflammatory Diseases", J MED. CHEM., (2012), vol. 55, doi:doi:10.1021/jm300847w, pages 8559 - 8581, XP055110817 DOI: http://dx.doi.org/10.1021/jm300847w | - MAXWELL ET AL., "Attenuation of phosphoinositide 3-kinase ? signaling restrains autoimmune disease", J AUTOIMMUN., (2012), vol. 38, doi:doi:10.1016/j.jaut.2012.04.001, pages 381 - 391, XP028488840 DOI: http://dx.doi.org/10.1016/j.jaut.2012.04.001 | - HAYLOCK-JACOBS ET AL., "PI3K? drives the pathogenesis of experimental autoimmune encephalomyelitis by inhibiting effector T cell apoptosis and promoting Thl7 differentiation", J AUTOIMMUN., (2011), vol. 36, doi:doi:10.1016/j.jaut.2011.02.006, pages 278 - 287, XP028226364 DOI: http://dx.doi.org/10.1016/j.jaut.2011.02.006 | - SOOND ET AL., "PI3K p110? regulates T-cell cytokine production during primary and secondary immune responses in mice and humans", BLOOD, (2010), vol. 115, no. 11, pages 2203 - 2213 | - CAMPS ET AL., "Blockade of PI3Ky suppresses joint inflammation and damage in mouse models of rheumatoid arthritis", NAT. MED., (2005), vol. 11, no. 9, doi:doi:10.1038/nm1284, pages 936 - 943, XP055105863 DOI: http://dx.doi.org/10.1038/nm1284 | - HAYLOCK-JACOBS ET AL., "PI3K8 drives the pathogenesis of experimental autoimmune encephalomyelitis by inhibiting effector T cell apoptosis and promoting Thl7 differentiation", J AUTOIMMUN., (2011), vol. 36, doi:doi:10.1016/j.jaut.2011.02.006, pages 278 - 287, XP028226364 DOI: http://dx.doi.org/10.1016/j.jaut.2011.02.006 | - SUBRAMANIAM ET AL., "Targeting Nonclassical Oncogenes for Therapy in T-ALL", CANCER CELL, (2012), vol. 21, doi:doi:10.1016/j.ccr.2012.02.029, pages 459 - 472, XP028410924 DOI: http://dx.doi.org/10.1016/j.ccr.2012.02.029 | - LANNUTTI ET AL., "CAL-101a p110? selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability", BLOOD, (2011), vol. 117, no. 2, doi:doi:10.1182/blood-2010-03-275305, pages 591 - 594, XP008152256 DOI: http://dx.doi.org/10.1182/blood-2010-03-275305 | - HOELLENRIEGEL ET AL., "The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leuckemia", BLOOD, (2011), vol. 118, no. 13, doi:doi:10.1182/blood-2011-05-352492, pages 3603 - 3612, XP002676784 DOI: http://dx.doi.org/10.1182/blood-2011-05-352492 | - BURGER, "Inhibiting B-Cell Receptor Signaling Pathways in Chronic Lymphocytic Leukemia", CURR. MEMATOL. MALIG. REP., (2012), vol. 7, doi:doi:10.1007/s11899-011-0104-z, pages 26 - 33, XP035015776 DOI: http://dx.doi.org/10.1007/s11899-011-0104-z | - HERISHANU ET AL., "The lymph node microenvironment promotes B-cell receptor signaling, NF- B activation, and tumor proliferation in chronic lymphocytic leukemia", BLOOD, (2011), vol. 117, no. 2, pages 563 - 574 | - DAVIS ET AL., "Chronic active B-cell-receptor signaling in diffuse large B-cell lymphoma", NATURE, (2010), vol. 463, doi:doi:10.1038/NATURE08638, pages 88 - 92, XP002646596 DOI: http://dx.doi.org/10.1038/NATURE08638 | - PIGHI ET AL., "Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling", CELL ONCOL. (DORDR), (2011), vol. 34, no. 2, pages 141 - 153 | - RIZZATTI ET AL., "Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGF? signaling pathways", BRIT. J HAEMATOL., (2005), vol. 130, pages 516 - 526 | - MARTINEZ ET AL., "The Molecular Signature of Mantle Cell Lymphoma Reveals Multiple Signals Favoring Cell Survival", CANCER RES., (2003), vol. 63, pages 8226 - 8232 | - KURTOVA ET AL., "Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance", BLOOD, (2009), vol. 114, no. 20, pages 4441 - 4450 | - BURGER ET AL., "High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation", BLOOD, (2009), vol. 113, no. 13, doi:doi:10.1182/blood-2008-07-170415, pages 3050 - 3058, XP055005241 DOI: http://dx.doi.org/10.1182/blood-2008-07-170415 | - QUIROGA ET AL., "B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406", BLOOD, (2009), vol. 114, no. 5, doi:doi:10.1182/blood-2009-03-212837, pages 1029 - 1037, XP055374645 DOI: http://dx.doi.org/10.1182/blood-2009-03-212837 | - NISITANI ET AL., "Posttranscriptional regulation of Bruton's tyrosine kinase expression in antigen receptor-stimulated splenic B cells", PNAS, (2000), vol. 97, no. 6, pages 2737 - 2742 | - DE WEERS ET AL., "The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages", EUR. J IMMUNOL., (1993), vol. 23, pages 3109 - 3114 | - SMITH ET AL., "Expression of Bruton's Agammaglobulinemia Tyrosine Kinase Gene, BTK, Is Selectively Down-Regulated in T Lymphocytes and Plasma Cells", J IMMUNOL., (1994), vol. 152, pages 557 - 565 | - RANDIS TM ET AL., EUR J IMMUNOL., (2008), vol. 38, no. 5, pages 1215 - 24 | - PINHO V, J IMMUNOL., (2007), vol. 179, no. 11, pages 7891 - 8 | - SADHU C. ET AL., J IMMUNOL., (2003), vol. 170, no. 5, pages 2647 - 54 | - CONDLIFFE AM ET AL., BLOOD, (2005), vol. 106, no. 4, pages 1432 - 40 | - KUTKARNI ET AL., IMMUNOLOGY, (2011), vol. 4, no. 168, pages 1 - 11 | - MARWICK JA ET AL., AM JRESPIR CRIT CARE MED., (2009), vol. 179, no. 7, pages 542 - 8 | - KONRAD S ET AL., J BIOL CHEM., (2008), vol. 283, no. 48, pages 33296 - 303 | - ALI K ET AL., NATURE, (2004), vol. 431, no. 7011, pages 1007 - 11 | - LEE KS ET AL., FASEB J., (2006), vol. 20, no. 3, pages 455 - 65 | - KIM MS ET AL., TRENDS IMMUNOL., (2008), vol. 29, no. 10, pages 493 - 501 | - GUO H ET AL., JEXP MED., (2008), vol. 205, no. 10, pages 2419 - 35 | - TASSI I ET AL., IMMUNITY, (2007), vol. 27, no. 2, pages 214 - 27 | - SAUDEMONT A, PROC NATL ACAD SCI USA., (2009), vol. 106, no. 14, pages 5795 - 800 | - KIM N ET AL., BLOOD, (2007), vol. 110, no. 9, pages 3202 - 8 | - WILLIAMS, O. ET AL., CHEM BIOL, (2010), vol. 17, no. 2, pages 123 - 34 | - BARBER, DF ET AL., J. IMMUNOL., (2006), vol. 176, no. 1, pages 589 - 93 | - ALI K ET AL., J IMMUNOL., (2008), vol. 180, no. 4, pages 2538 - 44 | - ALI K, NATURE, (2004), vol. 431, no. 7011, pages 1007 - 11 | - LEE KS ET AL., JALLERGY CLIN IMMUNOL, (2006), vol. 118, no. 2, pages 403 - 9 | - DOUKAS J ET AL., J PHARMACOL EXP THER., (2009), vol. 328, no. 3, pages 758 - 65 | - VOGT, PK ET AL., CURR TOP MICROBIOL IMMUNOL., (2010), vol. 347, pages 79 - 104 | - FRESNO VARA, JA ET AL., CANCER TREAT REV., (2004), vol. 30, no. 2, pages 193 - 204 | - ZHAO, L; VOGT, PK, ONCOGENE, (2008), vol. 27, no. 41, pages 5486 - 96 | - COURTNEY, KD ET AL., J CLIN ONCOL., (2010), vol. 28, no. 6, pages 1075 - 1083 | - MARKMAN, B ET AL., ANN ONCOL., (2010), vol. 21, no. 4, pages 683 - 91 | - KONG, D; YAMORI, T, CURR MED CHEM., (2009), vol. 16, no. 22, pages 2839 - 54 | - JIMENO, A ET AL., J CLIN ONCOL., (2009), vol. 27, page 156S | - FLINN, IW ET AL., JCLIN ONCOL., (2009), vol. 27, page 156S | - SHAPIRO, G ET AL., JCLIN ONCOL., (2009), vol. 27, page 146S | - WAGNER, AJ ET AL., J CLIN ONCOL., (2009), vol. 27, page 146S | - VOGT, PK ET AL., VIROLOGY, (2006), vol. 344, no. 1, pages 131 - 8 | - WARD, S ET AL., CHEM BIOL., (2003), vol. 10, no. 3, pages 207 - 13 | - SALMENA, L ET AL., CELL, (2008), vol. 133, pages 403 - 414 | - CHAPUIS, N ET AL., CLIN CANCER RES., (2010), vol. 16, no. 22, pages 5424 - 35 | - KHWAJA, A, CURR TOP MICROBIAL IMMUNOL., (2010), vol. 347, pages 169 - 88 | - HERRERA, VA ET AL., ANTICANCER RES., (2011), vol. 31, no. 3, pages 849 - 54 | - HALUSKA, F ET AL., SEMIN ONCOL., (2007), vol. 34, no. 6, pages 546 - 54 | - SARKER, D ET AL., CLIN CANCER RES., (2009), vol. 15, no. 15, pages 4799 - 805 | - CHEN, JS ET AL., MOL CANCER THER., (2008), vol. 7, pages 841 - 850 | - BANSAL, N ET AL., CANCER CONTROL., (2009), vol. 16, no. 1, pages 8 - 13 | - FURUKAWA, T, J GASTROENTEROL., (2008), vol. 43, no. 12, pages 905 - 11 | - PORTA, C; FIGLIN, RA, J UROL., (2009), vol. 182, no. 6, pages 2569 - 77 | - SAIF, MW; CHU, E, CANCER J, (2010), vol. 16, no. 3, pages 196 - 201 | - TORBETT, NE ET AL., BIOCHEM J., (2008), vol. 415, pages 97 - 100 | - BRZEZIANSKA, E; PASTUSZAK-LEWANDOSKA, D, FRONT BIOSCI., (2011), vol. 16, pages 422 - 39 | - MAZZOLETTI, M; BROGGINI, M, CURR MED CHEM., (2010), vol. 17, no. 36, pages 4433 - 47 | - CHEN J.S. ET AL., MOL CANCER THER., (2008), vol. 7, no. 4, pages 841 - 50 | - IKEDA H. ET AL., BLOOD, (2010), vol. 116, no. 9, pages 1460 - 8 | - BILLOTTET C ET AL., ONCOGENE, (2006), vol. 25, no. 50, pages 6648 - 59 | - BILLOTTET C ET AL., CANCER RES., (2009), vol. 69, no. 3, pages 1027 - 36 | - IKEDA H ET AL., BLOOD, (2010), vol. 116, no. 9, pages 1460 - 8 | - HERMAN SE ET AL., BLOOD, (2010), vol. 116, no. 12, pages 2078 - 88 | - HERMAN SE ET AL., BLOOD, (2011), vol. 117, no. 16, pages 4323 - 7 | - LANNUTTI BJ ET AL., BLOOD, (2011), vol. 117, no. 2, pages 591 - 4 | - WARD S ET AL., CHEM BIOL., (2003), vol. 10, no. 3, pages 207 - 13 | - GENG L ET AL., CANCER RES., (2004), vol. 64, no. 14, pages 4893 - 9 | - SCHMID ET AL., CANCER CELL, (2011), vol. 19, pages 715 - 727 | - CIRAOLO ET AL., MOLECULAR BIOLOGY OF THE CELL, (2010), vol. 21, pages 704 - 711 | - BI ET AL., J BIOL CHEM, (1999), vol. 274, pages 10963 - 10968 | - KULKARNI ET AL., SCIENCE, (2000), vol. 287, pages 1049 - 1053 | - GARVEY, M.A. ET AL., J CHILD NEUROL., (2005), vol. 20, pages 424 - 429 | - ASBAHR, F.R. ET AL., 4M. J PSYCHIATRY, (1998), vol. 155, pages 1122 - 1124 | - HIRSCHTRITT, M.E. ET AL., CHILD NEUROPSYCHOL., (2008), vol. 1, pages 1 - 16 | - PETERSON, B.S. ET AL., ARCH. GEN. PSYCHIATRY, (2000), vol. 57, pages 364 - 372 | - SOKOL, M.S., J CHILD ADOLESC. PSYCHOPHARMACOL., (2000), vol. 10, pages 133 - 145 | - SOKOL, M.S. ET AL., 4M. J PSYCHIATRY, (2002), vol. 159, pages 1430 - 1432 | - LESLIE, D.L. ET AL., J. AM. ACAD. CHILD ADOLESC. PSYCHIATRY, (2008), vol. 47, pages 1166 - 1172 | - HOLLANDER, E. ET AL., AM. J. PSYCHIATRY, (1999), vol. 156, pages 317 - 320 | - MARGUTTI, P. ET AL., CURR. NEUROVASC. RES., (2006), vol. 3, pages 149 - 157 | - KURLAN, R.; KAPLAN, E.L., PEDIATRICS, (2004), vol. 113, pages 883 - 886 | - GARVEY, M.A. ET AL., J CLIN. NEUROL., (1998), vol. 13, pages 413 - 423 | - KIRVAN. C.A. ET AL., J. NEUROIMMUNOL., (2006), vol. 179, pages 173 - 179 | - YADDANAPUDI, K. ET AL., MOL. PSYCHIATRY, (2010), vol. 15, pages 712 - 726 | - HOFFMAN, K.I. ET AL., J NEUROSCI., (2004), vol. 24, pages 1780 - 1791 | - LEE ET AL., J ALLERGY CLIN IMMUNOL, (2006), vol. 118, no. 2, pages 403 - 9 | - WILFIAMS ET AL., CHEM BIOL, (2010), vol. 17, no. 2, pages 123 - 34 | - BOEHNCKE ET AL., CLINICS IN DERMATOLOGY, (2007), vol. 25, pages 596 - 605 | - CHEVATIER ET AL., KIDNEY INTERNATIONAL, (2009), vol. 75, pages 1145 - 1152 | - MOORE; HOGABOAM, AM. J. PHYSIOL. LUNG. CELL. MOL. PHYSIOL., (2008), vol. 294, pages L152 - L160 | - CHUANG ET AL., CLIN LIVER DIS, (2008), vol. 12, pages 333 - 347 | - OMENETTI, A. ET AL., LABORATORY INVESTIGATION, (2007), vol. 87, pages 499 - 514 | - VARICCHIO, L. ET AL., EXPERT REV. HEMATOL., (2009), vol. 2, no. 3, pages 315 - 334 | - YAMAMOTO ET AL., JLNVEST DERMATOL, (1999), vol. 112, pages 456 - 462 | - PHYANAGI ET AL., ARTHRITIS & RHEUMATISM, (2009), vol. 60, no. 10, pages 3118 - 3127 | - GHOREISHI ET AL., LUPUS, (2009), vol. 19, pages 1029 - 1035 | - OHL ET AL., JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, (2011), page 14 | - XIA ET AL., RHEUMATOLOGY, (2011), vol. 50, pages 2187 - 2196 | - PAU ET AL., PL S ONE, (2012), vol. 7, no. 5, page E36761 | - MUSTAFA ET AL., TOXICOLOGY, (2011), vol. 290, pages 156 - 168 | - ICHIKAWA ET AL., ARTHRITIS AND RHEUMATISM, (2012), vol. 62, no. 2, pages 493 - 503 | - OUYANG ET AL., J MOL MED, (2012), page 10 | - RANKIN ET AL., JOURNAL OF IMMUNOLOGY, (2012), vol. 188, pages 1656 - 1667 | - CHIORINI ET AL., JOURNAL OFAUTOIMMUNITY, (2009), vol. 33, pages 190 - 196 | - DENTON, C.P. ET AL., NATURE CLINICAL PRACTICE RHEUMATOLOGY, (2006), vol. 2, no. 3, pages 134 - 143 | - WENZEL ET AL., LUPUS, (2010), vol. 19, pages 1020 - 1028 | - S. M. ELBASHIR ET AL., NATURE, (2001), vol. 411, pages 494 - 498 | - VON HOFF D. ET AL., N ENGL. J MED., (2009), vol. 361, no. 12, pages 1164 - 72 | - ROBARGE K.D. ET AL., BIOORG MED CHEM LETT., (2009), vol. 19, no. 19, pages 5576 - 81 | - YAUCH, R. L. ET AL., SCIENCE, (2009), vol. 326, pages 572 - 574 | - RUDIN, C. ET AL., NEW ENGLAND JOF MEDICINE, (2009), pages 361 - 366 | - SIU L. ET AL., J CLIN. ONCOL., (2010), vol. 28, page 15S | - PAN S. ET AL., ACS MED. CHEM. LETT., (2010), vol. 1, no. 3, pages 130 - 134 | - ROMINGER C.M. ET AL., J PHARMACOL. EXP. THER., (2009), vol. 329, no. 3, pages 995 - 1005 | - LUCAS B.S. ET AL., BIOORG. MED. CHEM. LETT., (2010), vol. 20, no. 12, pages 3618 - 22 | - GOODMAN; GILMAN'S, The Pharmacological Basis of Therapeutics | - CANCER CELL, (2005), vol. 7, page 468 | - CANCER RES., (1984), vol. 44, pages 717 - 726 | - SCIENCE, (2010), vol. 330, page 827 | - PNAS, (2010), vol. 107, page 4275 | - RAPID COMMUN. MASS SPECTROM., vol. 10, pages 1019 - 1026 | - METHODS ENZYMOL., (2007), vol. 434, pages 131 - 54 | - S. BOLLAND; J.V. RAVTECH, IMMUNITY, (2000), vol. 12, pages 277 - 285 | - T. WU ET AL., J CLIN INVEST., vol. 117, pages 2186 - 2196 | - NATURE MEDICINE, (2008), vol. 14, pages 748 - 755 | - CANCER GENET CYTOGENET, (200508), vol. 161, no. 1, pages 51 - 6 | - NIALS ET AL., DIS MODEL MECH., (2008), vol. 1, no. 4-5, pages 213 - 220 | - HONG ET AL., J IMMUNOL., (1999), vol. 162, pages 7480 - 7491 | - YAMAMOTO ET AL., J INVEST DERMATOL, (1999), vol. 112, pages 456 - 462 | - HARGIS ET AL., AJP, (1985), vol. 120, no. 2, pages 323 - 325 | - CHIORINI ET AL., JOURNAL OF AUTOIMMUNITY, (2009), vol. 33, pages 190 - 196 | - JONSSON ET AL., CLIN IMMUNOL IMMUNOPATHOL, (1987), vol. 42, pages 93 - 101 | - DESHMUKH ET AL., J ORAL PATHOL MED, (2009), vol. 38, pages 42 - 27 | - CHA ET AL., ARTHRITIS RHEUM, (2002), vol. 46, pages 1390 - 1398 | - KONG ET AL., CLIN EXP RHEUMATOL, (1998), vol. 16, pages 675 - 681 | - PODOLIN ET AL., JEXP MED, (1993), vol. 178, pages 793 - 803 | - RASOOLY ET AL., CLIN IMMUNOL IMMUNOPATHOL, (1996), vol. 81, pages 287 - 292 | - LI ET AL., IMMUNITY, (2004), vol. 21, pages 551 - 560 | - OAK ET AL., PROC NATL ACAD SCI USA, (2006), vol. 103, pages 16882 - 16887 | - GROOM ET AL., J CLIN INVEST, (2002), vol. 109, pages 59 - 68 | - OH-HORA ET AL., NAT. IMMUNOL, (2008), vol. 9, pages 432 - 443 | - NISHIMORI ET AL., JIMMUNOL, (1995), vol. 154, pages 4865 - 4873 | - SHEN ET AL., J IMMUNOL, (2006), vol. 177, pages 5676 - 5686 | - MCGRATH-MORROW ET AL., AM JPHYSIOL LUNG CELL MOL PHYSIOL, (2006), vol. 291, pages L837 - 846 | - KONRAD ET AL., IOURRZAL OFBIOLOGICAL CHEMISTRY, (2008), vol. 283, no. 48, pages 33296 - 33303 | - HE ET AL., LEUKEMIA RESEARCH, (2009), vol. 33, pages 798 - 802 | - CAMPS ET AL., NATURE MEDICINE, (2005), vol. 11, no. 9, pages 936 - 943 | EP19970304971 | WO1998IB01113 | EP19990302232 | GB19990012961 | US19990148464 | EP19990308617 |